Price$27.90+0.15 (+0.54%)
02:00 PM07:15 PM
News · 26 weeks41+150%
2025-10-262026-04-19
Mix1190d
- Insider4(36%)
- SEC Filings3(27%)
- Earnings3(27%)
- Other1(9%)
Latest news
25 items- INSIDERSEC Form 4 filed by Valauri Christina Rizopoulos4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERSEC Form 4 filed by Cossman Jeffrey4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERSEC Form 4 filed by Cohen David Seth4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERSEC Form 4 filed by Sabet Ahmed Zaki4 - Precipio, Inc. (0001043961) (Issuer)
- SECSEC Form 10-K filed by Precipio Inc.10-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio Announces Q4 and year-end 2025 Shareholder Update CallNEW HAVEN, Conn., March 12, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), will be hosting its Q4 and year end 2025 corporate update call on April 2nd, 2026 at 5:00 PM ET. The call will include updates on all of the company's current core businesses. The conference call may be accessed by calling 646.307.1865. All callers should ask for the Precipio Inc. conference call. Listeners interested in submitting questions in advance should email their questions to investors@precipiodx.com and management will do its best to address those questions during the call. A replay of the call will be available approximately 24 hours after the call and may be
- PRPrecipio Announces Publication of a Joint Study with Memorial Sloan-Kettering Cancer Center Highlighting Its Cutting-Edge Bloodhound BCR::ABL1 AssayNEW HAVEN, Conn., March 10, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has announced the publication1 in the Journal of Clinical Pathology of a study conducted in collaboration with the Memorial Sloan-Kettering Cancer Center, demonstrating Precipio's new Bloodhound BCR::ABL1 assay for Chronic Myeloid Leukemia (CML). According to the publication's authors: "Its ease of use facilitates broad implementation and accessibility across clinical laboratories and resource settings." Ilan Danieli, CEO of Precipio, expanded on these findings. "Our Bloodhound BCR::ABL1 assay is the first and only assay that simultaneously detects and quantifies all fou
- SECPrecipio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Precipio, Inc. (0001043961) (Filer)
- PRPrecipio 2025 (Unaudited) Revenues Grew to $24.0M, a 30% Increase Year-Over-YearNEW HAVEN, Conn., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces some preliminary (unaudited) financials for Q4-2025 and for its fiscal year 2025. Below are some of the key financial performance metrics for the Company. Revenue Growth – Precipio's revenues increased from $18.5M in 2024 to $24.0M in 2025, an increase of 30% year over year. Q4-2025 revenues were $6.7M, an increase of 23% YoY from $5.4M in Q4-2024. Positive Adjusted EBITDA – Precipio will report Adjusted EBITDA of $0.95M for Q4-2025, and $1.23M for the full year 2025. This is compared to Adjusted EBITDA of $0.40M in Q4-2024 and ($1.5M) in full year 2024. Please
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Precipio Inc.SCHEDULE 13G/A - Precipio, Inc. (0001043961) (Subject)
- SECSEC Form S-8 filed by Precipio Inc.S-8 - Precipio, Inc. (0001043961) (Filer)
- NEWSDealFlow Discovery Conference Announces Initial Lineup of Presenting Companies Ahead of Next Week's EventATLANTIC CITY, NJ / ACCESS Newswire / January 23, 2026 / DealFlow Events today announced the growing list of companies scheduled to present and participate in one-on-one meetings with investors and analysts at the DealFlow Discovery Conference, taking place January 28-29, 2026, at the Borgata Hotel Casino & Spa in Atlantic City.More than 100 public and private companies are expected to participate in the conference, which brings together investors, analysts, growth company executives, and capital markets professionals for two days of company presentations, structured networking, and pre-scheduled 1:1 meetings.Below is the current list of companies confirmed to present and take meetings. Publ
- INSIDERAmendment: Director Andrews Ronald Asbury was granted 568 shares, increasing direct ownership by 4% to 15,796 units (SEC Form 4)4/A - Precipio, Inc. (0001043961) (Issuer)
- INSIDERAmendment: Director Cohen David Seth was granted 746 shares, increasing direct ownership by 1% to 53,688 units (SEC Form 4)4/A - Precipio, Inc. (0001043961) (Issuer)
- INSIDERAmendment: Director Cossman Jeffrey was granted 597 shares, increasing direct ownership by 4% to 15,340 units (SEC Form 4)4/A - Precipio, Inc. (0001043961) (Issuer)
- INSIDERAmendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)4/A - Precipio, Inc. (0001043961) (Issuer)
- INSIDERAmendment: Chief Operating Officer Sabet Ahmed Zaki bought $488 worth of shares (25 units at $19.50), increasing direct ownership by 3% to 995 units (SEC Form 4)4/A - Precipio, Inc. (0001043961) (Issuer)
- INSIDERAmendment: Chief Operating Officer Sabet Ahmed Zaki bought $505 worth of shares (31 units at $16.30), increasing direct ownership by 3% to 970 units (SEC Form 4)4/A - Precipio, Inc. (0001043961) (Issuer)
- INSIDERDirector Cohen David Seth was granted 546 shares, increasing direct ownership by 1% to 54,234 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERDirector Cossman Jeffrey was granted 437 shares, increasing direct ownership by 3% to 15,777 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERDirector Laporte Kathleen was granted 520 shares, increasing direct ownership by 8% to 7,382 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERDirector Valauri Christina Rizopoulos was granted 406 shares, increasing direct ownership by 8% to 5,427 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)
- PRPrecipio Takes Major Steps Toward a Clean Balance SheetNEW HAVEN, Conn., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) has made major strides in cleaning up its balance sheet with two major accomplishments: 1. Major obligation repaid A $1.1 million advance from Change Healthcare ("CHC"), the Company's clearinghouse service for billing claims processing, has been repaid. CHC experienced a cybersecurity incident in 2024 and advanced Precipio and others funds to cover collections shortfalls. In early January 2026, the Company completed its repayment of that advance. Precipio maintains a small loan with the Connecticut Department of Economic and Community Development in the approximate princ
- INSIDERSEC Form 4 filed by Director Valauri Christina Rizopoulos4 - Precipio, Inc. (0001043961) (Issuer)
- INSIDERChief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 3% to 735 units (SEC Form 4)4 - Precipio, Inc. (0001043961) (Issuer)